Pharma Journalist -

Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing…
Read More...

Celgene Corporation announced the U.S. Food and Drug Administration (FDA) approved REVLIMID (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult…
Read More...

Pfizer Inc. announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized…
Read More...

AveXis, a Novartis company, announced innovative access programs for Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with…
Read More...

Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi (ruxolitinib) for the treatment of steroid-refractory acute GVHD in adult and pediatric…
Read More...

Pfizer Inc. announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized…
Read More...

AveXis, a Novartis company, announced the US Food and Drug Administration (FDA) has approved Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than…
Read More...

GlaxoSmithKline plc announced that the National Medical Products Administration (NMPA) has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 years or…
Read More...

ProBioGen AG announced the closing of a services and license agreement with Abcuro, Inc. Pursuing a new generation of immune modulatory bio-therapeutics, Abcuro has developed a new…
Read More...

Santhera Pharmaceuticals announces that it has entered into an exclusive license agreement with Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group),…
Read More...